Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immunicum, a developer of cancer vaccines, has received approval from the Swedish Medical Products Agency to commence its first clinical trial using dendritic cell-based cancer vaccine and has secured financing to complete the clinical trial.
Subscribe to our email newsletter
Immunicum’s vaccine is based on using dendritic cells from healthy individuals and can be mass-produced, leading to commercial advantages, the company said.
The study will be conducted on kidney cancer patients at the University Hospital in Uppsala.
A clinical phase I/II trial will begin on twelve patients with metastatic renal cancer, which would evaluate the safety and efficacy of the vaccine.